Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Clinical trial

NCT06382948

1 development in the corpus

NCT06382948

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 20, 2026 · PHASE 3 TRIAL

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

ClinicalTrials.gov

This is a Phase 3 trial registration with no results posted; the planned design is rigorous but outcomes remain unknown and unverified.

PreliminaryNCT06382948 HER2 Negative Breast Cancer Elacestrant

Reported

Planned enrollment300

Primary outcome measureProgression-free survival (PFS) by BIRC

Study phasePhase 3

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support